These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34564979)

  • 1. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
    Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
    J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
    Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y
    BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
    Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
    Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
    Fisher OM; Brown C; Esquivel J; Larsen SG; Liauw W; Alzahrani NA; Morris DL; Kepenekian V; Sourrouille I; Dumont F; Tuech JJ; Ceribelli C; Doussot B; Sgarbura O; Alhosni M; Quenet F; Glehen O; Cashin PH;
    BJS Open; 2024 May; 8(3):. PubMed ID: 38722737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
    Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin.
    Papageorgopoulou C; Nikolakopoulos K; Seretis C
    Chirurgia (Bucur); 2022 Jun; 117(3):266-277. PubMed ID: 35792537
    [No Abstract]   [Full Text] [Related]  

  • 11. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
    Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
    Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
    Moaven O; Votanopoulos KI; Shen P; Mansfield P; Bartlett DL; Russell G; McQuellon R; Stewart JH; Levine EA
    Ann Surg Oncol; 2020 Mar; 27(3):772-780. PubMed ID: 31720933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
    Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
    Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).
    van de Vlasakker VCJ; Lurvink RJ; Cashin PH; Ceelen W; Deraco M; Goéré D; González-Moreno S; Lehmann K; Li Y; Moran B; Morris DL; Piso P; Quadros CA; Rau B; Somashekhar SP; Sommariva A; van der Speeten K; Spiliotis J; Sugarbaker PH; Teo MCC; Verwaal VJ; Yonemura Y; Glehen O; de Hingh IHJT
    Eur J Surg Oncol; 2021 Nov; 47(11):2888-2892. PubMed ID: 34020808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
    Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
    Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.